Seeking Alpha
30 Sept 2026, 23:42 UTC · 7w ago
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
Impact · against what's priced in
Sagimet (SGMT) is providing updates on 52-week Phase 3 data and U.S. expansion plans for its acne drug Denifanstat. This represents positive clinical progress and strategic scaling for the lead candidate.
- SGMT+0.20
No priced-in read yet




